Goulooze S.C., Yang S, Mesic E, Beerahee M, Post T.M, Mahar K.M. Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]
Goulooze S.C., Noort van M., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat). PAGE 2023 [Link to publication]
Noort van M., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]
Mahar K.M., Goulooze S.C., Yang S., Mesic E., Beerahee M., Post T.M. Population pharmacokinetics of daprodustat across five phase 2b/3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Noort van N., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population Dose-Hgb modelling of daprodustat across five Phase 3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Goulooze S.C., Noort van N., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population doe-hemoglobin model for daprodustat. ACoP 2022. Link to publication
Willmann S., Marostica E., Snelder N., Solms A., Jensen M., Lobmeyer M., Lensing A. W. A., Bethune C., Morgan E., Yu R. Z., Wang Y., Jung S. W., Geary R., Bhanot S. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst.…
Berg van der P., Post T., Ahsman M., Berg van der P., Hooijmaijers R., Snelder N., Yang S., ., Vasist L., Mahar K., Visser S. Population Dose-Response Analysis of Hemoglobin Data From Global Phase 2 and Japanese Phase 3 Studies With Daprodustat in Chronic Kidney Disease Patients With Anemia Following Once Daily (OD) or 3x…
Mahar K., Post T., Ahsman M., Berg van der P., Hooijmaijers R., Snelder N., Vasist L., Visser S. Population Pharmacokinetic Analysis of Daprodustat in Healthy Volunteers (HV), Global Phase 2 and Japanese Phase 3 Studies in Chronic Kidney Disease Patients with Anemia Following Once Daily (QD) or 3x Weekly (TIW) Administration. ASCPT 2021.
Snelder N., Post T., Berg van der P., Hooijmaijers R., Ahsman M., Vasist L., Mahar K., Visser S. Population Pharamcokinetic/pharmacodynamics (PKPD) Analysis of EPO during daprodustat treatment in healthy volunteers (HV) and chronic kidney disease (CKD) patients with Anemia. ASCPT 2021.